Page 25 - 2022_01-Haematologica-web

Individualized first-line management of FL
Haematol. 2014 ;1(1):e17-27.
24.Trotman J, Barrington SF, Belada D, et al.
Prognostic value of end-of-induction PET response after first-line immunochemother- apy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1530-1542.
25. Federico M, Mannina D, Versari A, et al. Response oriented maintenance therapy in advanced follicular lymphoma. Results of the interim analysis of the FOLL 12 trial con- ducted by the Fondazione Italiana Linfomi. Hematol Oncol. 2019 ;37(S2):153-154.
26. Pettitt AR, Barrington S, Kalakonda N, et al. NCRI PETReA trial: a phase 3 evaluation of PET-guided, response adapted therapy in patients with previously untreated, advanced stage, high-tumour-burden follicu- lar lymphoma. Hematol Oncol. 2019;37 (S2):67-68.
27. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15(3):1110-1117.
28.Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522.
29. Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival-a study from the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2009 ;28(5):822-829.
30. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognos- tic index. Blood. 2004;104(5):1258-1265.
31. Federico M, Bellei M, Marsheselli L, et al. Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognos- tic factor project. J Clin Oncol. 2009;27(27):4555-4562.
32. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prog- nostication for patients receiving first-line immunochemotherapy for follicular lym- phoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16(9):1111-1122.
33.Huet S, Tesson B, Jais JP, et al. A gene- expression profiling score for prediction of outcome in patients with follicular lym- phoma: a retrospective training and valida- tion analysis in three international cohorts. Lancet Oncol. 2018;19(4):549-561.
34. Maurer MJ, Bachy E, Ghesquières H, et al. 2016 Early event status informs subsequent outcome in newly diagnosed follicular lym- phoma. Am J Hematol. 2016;91(11):1096- 1101.
35. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J Clin Oncol. 2009;27(8):1202-1208.
36. Barraclough A, Bishton M, Cheah C, et al. The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. Br J Haematol. 2021;195(1):15-24.
37.Batlevi C, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: sur- vival, treatment outcome, and identification
of high-risk subgroups. Blood Cancer J.
2020;10(7):74.
38. Casulo C, Byrtek M, Dawson KL, et al. Early
relapse of follicular lymphoma after ritux- imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33(23):2516-2522.
39.Batlevi C, Sha F, Alperovich A, et al. Positron-emission tomography-based stag- ing reduces the prognostic impact of early disease progression in patients with follicu- lar lymphoma. Eur J Cancer. 2020;126:78-90.
40. Wagner-Johnston ND, Link BK, Byrtek M, et al. Outcomes of transformed follicular lym- phoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood. 2015;126(7):851-857.
41. Sarkozy C, Trneny M, Xerri L, et al. Risk fac- tors and outcomes for patients with follicu- lar lymphoma who had histologic transfor- mation after response to first-line immunochemotherapy in the PRIMA trial. J Clin Oncol. 2016;34(22):2575-2582.
42. Federico M, Callabero Barrigon MD, Marsheselli L, et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. Lancet Haematol. 2018;5(8):359-367.
43. Soubeyran P, Eghbali H, Trojani M, et al. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7(7):713.
44. Michallet AS, Lebras L, Bauwens D, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol. 2013;6:45.
45. Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368-3375.
46. MacManus M, Fisher R, Roos D, et al. Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03. J Clin Oncol. 2018;36(29):2918-2925.
47. Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non- Hodgkin lymphoma: a randomized phase III trial. Radiother Oncol. 2011;100(1):86-92.
48. Hoskin P, Popova B, Schofield O, et al. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22(3):332-340.
49.Kahl B, Hong F, Williams ME, et al. Rituximab extended schedule or re-treat- ment trial for low–tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol E4402. J Clin Oncol. 2014;32(28):3096-3102.
50. Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma signifi- cantly increases event-free survival and response duration compared with the stan- dard weekly x 4 schedule. Blood. 2004;103 (12):4416-4423.
51. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and pred- nisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579-4586.
52.Bachy E, Houot R, Morschhauser F, et al. Long-term follow-up of the FL2000 study comparing CHVP-interferon plus rituximab
in follicular lymphoma. Haematologica.
2013;98(7):1107-1114.
53. Herold M, Haas A, Srock S, et al. Rituximab
added to first-line mitoxantrone, chloram- bucil, and prednisolone chemotherapy fol- lowed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25(15):1986-1992.
54. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, dox- orubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective ran- domized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106 (12):3725-3732.
55. Shulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non- Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007;(4):CD003805.
56. Lockmer S, Østenstad B, Hagberg H, et al. Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol. 2018;38(33):3315-3323.
57. Kahl B, Burke J, van der Jagt R, et al. Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analy- sis from the BRIGHT trial. Blood. 2017;130(Suppl 1):484.
58. Federico M, Luminari S, Dondi A, et al. R- CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced- stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12): 1506-1513.
59. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, ran- domised, phase 3. Lancet. 2013;381(9873): 1203-1210.
60. Flinn IW, van der Jagt R, Kahl B, et al. First- line treatment of patients with indolent non- Hodgkin lymphoma or mantle-cell lym- phoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol. 2019;37(12):984-991.
61.Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017; 377(14):1331-1344.
62. Morschhauser F, Fowler N, Bouabdallah R, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934-947.
63.Townsend W, Buske C, Cartron G, et al. Obinutuzumab-based immunochemothera- py prolongs progression-free survival and time to next anti-lymphoma treatment in patients with previously untreated follicular lymphoma: four-year results from the phase III GALLIUM study. Blood. 2018;132(Suppl 1):1597.
64. Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy with obinu- tuzumab or rituximab for previously untreated follicular lymphoma in the GAL- LIUM study: influence of chemotherapy on
haematologica | 2022; 107(1)
17